ClinicalTrials.gg
Sign In
Drug

CG 400549 clinical trials

Also written CG400549.

studies test it
3
open now
0
in phase 3
0
first study started
2009

How each study uses CG 400549 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

CG400549
2

Studies by the year they started

3 studies that test it; most in 2009 (1)

Studies that test CG 400549, by start year
YearStudies
20091
20101
20121

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1

Who runs them

Industry 3 · Other 0

CrystalGenomics, Inc. (3)

Studies

Open first, then newest update. How each study uses CG 400549 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Codes

What other systems call CG 400549 · ClinicalTrials.gg INT005171

  • UNII (FDA) 4X6T64D64XNILOFABICINConfirmed FDA, Wikidata
  • Wikidata Q27260632cg-400549Confirmed FDA, Wikidata
  • DrugBank DB12347One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.